Virtual cutaneous area severity index (vCASI): A comprehensive methodology for quantitative skin disease assessment on positron emission tomography images
- PMID: 40545498
- DOI: 10.1007/s00259-025-07423-8
Virtual cutaneous area severity index (vCASI): A comprehensive methodology for quantitative skin disease assessment on positron emission tomography images
Abstract
Purpose: Quantification of skin diseases such as cutaneous lymphoma or psoriasis is important for pretreatment planning and response assessment. Currently, this quantification relies on clinical assessments, which are cumbersome, error-prone, and subject to inter-reader variability. FDG-PET/CT is a widely used molecular imaging technique for non-invasive detection and quantification of metabolically active disorders, providing biomarkers of disease extent, severity, and therapeutic response. However, skin disease quantification from PET/CT images remains challenging, error-prone, and labor-intensive.
Methods: We proposed a novel comprehensive methodology called virtual Cutaneous Area Severity Index (vCASI) to quantitatively assess the extent and severity of metabolically active skin disease from FDG-PET/CT images. Firstly, we used an automated body region localization method, followed by a standardization technique for PET images to reduce interscan measurement variability. Then, we generated skin shell PET images and developed a standardized Maximum Intensity Projection (MIP) rendering technique to enable reproducible 3D visualization of the skin with the disease. Finally, we introduced and validated a new quantitative scoring system (vCASI score) to measure the extent and severity of skin disease via these renderings.
Results: Correlations between vCASI scores and reference standard ground-truth assessments increased following the standardization of PET images, further improved with the use of adjusted mean of maximum percentile intensity values as the reference point for MIP rendering, and reached as high as 0.605. Additionally, correlations between repeated vCASI score assessments for the torso, thorax, abdomen, and pelvis exceeded 0.85, demonstrating high repeatability.
Conclusions: The vCASI methodology allows for accurate and reproducible quantitative assessment of the extent and severity of metabolically active skin diseases, such as cutaneous lymphoma and psoriasis, from FDG-PET/CT images. It addresses the challenges related to body region localization, non-standardness of PET images, robust visualization, and standardized display of PET images to detect and quantify skin disease. Additionally, it overcomes the lack of a practical and validated scoring system for quantifying skin disease on PET images. We demonstrated that the vCASI scoring system has high repeatability and good accuracy, and is optimized by the proposed methodology.
Keywords: Cutaneous lymphoma; Positron emission tomography; Psoriasis; Quantification; Scoring system; Skin disease.
© 2025. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Conflict of interest statement
Declarations. Ethics approval and consent to participate: This retrospective study was performed in line with the principles of the Declaration of Helsinki and the Belmont Report. Approval was granted by the Institutional Review Board of the University of Pennsylvania along with a HIPAA waiver and informed consent waiver. Consent to publish: Not applicable. Competing interests: The authors have no relevant financial or non-financial interests to disclose.
Similar articles
-
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4. Cochrane Database Syst Rev. 2021. Update in: Cochrane Database Syst Rev. 2022 May 23;5:CD011535. doi: 10.1002/14651858.CD011535.pub5. PMID: 33871055 Free PMC article. Updated.
-
Fluorine-18-fluorodeoxyglucose (FDG) positron emission tomography (PET) computed tomography (CT) for the detection of bone, lung, and lymph node metastases in rhabdomyosarcoma.Cochrane Database Syst Rev. 2021 Nov 9;11(11):CD012325. doi: 10.1002/14651858.CD012325.pub2. Cochrane Database Syst Rev. 2021. PMID: 34753195 Free PMC article.
-
The measurement and monitoring of surgical adverse events.Health Technol Assess. 2001;5(22):1-194. doi: 10.3310/hta5220. Health Technol Assess. 2001. PMID: 11532239
-
[Narrow-band UVB therapy in psoriasis vulgaris: good practice guideline and recommendations of the French Society of Photodermatology].Ann Dermatol Venereol. 2010 Jan;137(1):21-31. doi: 10.1016/j.annder.2009.12.004. Epub 2009 Dec 29. Ann Dermatol Venereol. 2010. PMID: 20110064 French.
-
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3. Cochrane Database Syst Rev. 2022. PMID: 35593186 Free PMC article.
References
-
- Lakhani R, Prakash C, Tiwari S, Purohit S, Paliwal V, Mathur DK, Bhargava P. Scoring system in dermatology: a review. J Dental Med Sci. 2016;15:89–99.
-
- Wu AG, Conway J, Barazani L, Roy B, Cline A, Pereira F. Is clear always clear? Comparison of Psoriasis Area and Severity Index (PASI) and the Physician’s Global Assessment (PGA) in psoriasis clearance. Dermatol Ther. 2020;10:1155–63. - DOI
-
- Uysal Pİ, Akdoğan N, Falay M, Şahin B, Özet G, Yalçın B. The importance of baseline screening investigations and modified severity weighted assessment tool in patients with early stage mycosis fungoides: A Four-year retrospective study. Turk J Dermatol. 2019;13:1–7. - DOI
-
- Cevenini G, Furini S, Barbini P, Tognetti L, Rubegni P. Scoring systems in dermatology. In2016 IEEE Int Symp Med Meas Appl. 2016;1–6. https://doi.org/10.1109/MeMeA.2016.7533793
Grants and funding
LinkOut - more resources
Full Text Sources